Episode Learning ObjectivesDiscuss appropriate assessment strategies for disease activity and prognosis to guide treatment decisions for moderate to severe plaque psoriasisApply current evidence and guidelines on targeted biologics with shared decision-making to make effective individualized treatment decisions for patients with moderate-to-severe plaque PsO (specifically ixekizumab and Guselkumab)Implement evidence-based and expert consensus strategies to improve interprofessional care coordination and address the needs of patients with comorbiditiesABOUT DR.CHRISTINA HAN, MD, FRCPC:Dr. Christina Han is a dermatologist practicing medical and surgical dermatology in Vancouver, BC and is certified to practice in both the United States and Canada. She sees a broad range of dermatology patients, including pediatric and adults and focuses her practice on medical dermatology. Her clinical focus includes inflammatory conditions, including psoriasis, atopic dermatitis, and acne. She also teaches medical students and residents and is a Clinical Assistant Professor with the Department of Dermatology at UBC. Disclaimer: This is an educational podcast only and does not replace professional medical advice. Please consult your healthcare provider for any health issues. Supported by IMEs from  Janssen and Lilly www.skinandjoints.ca
📻www.skinandjoints.ca✉️[email protected] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ver todos los episodios